National Clinical Practice Recommendations for Management of Diabetes Mellitus 2019

Objectives

Provide an Egyptian, evidence-informed national framework for prevention, diagnosis, treatment and quality improvement across the diabetes continuum, adapting international guidance to local cultural and health-service circumstances. The framework seeks to reduce non-communicable disease risks and diabetes-related morbidity through early detection, integrated and personalised management, prevention of acute events and chronic complications, and more efficient use of human and economic resources.[1][2]

• Strengthen prevention of type 2 diabetes among people with prediabetes through weight management, healthier diets, physical activity, risk-factor counselling and, in selected circumstances, metformin where lifestyle measures are ineffective or infeasible.[3]
• Detect diabetes early through risk-based opportunistic screening, fasting plasma glucose testing, antenatal assessment for gestational diabetes, and diagnostic pathways that distinguish type 1, type 2, gestational and other specific forms of diabetes.[4][5][6]
• Achieve individualised glycaemic management, generally aiming for glycated haemoglobin below 7% in adults where this can be attained safely, while modifying targets for children, older people, pregnancy, frailty, comorbidity, limited life expectancy and hypoglycaemia risk.[5][7][8][9]
• Provide nutrition therapy, physical-activity support, weight management and structured self-management education as core components of care rather than relying solely on pharmacological treatment.[8][10][11][12]
• Deliver safe pharmacological care for type 2 diabetes, normally beginning with metformin when tolerated and not contraindicated, intensifying treatment according to glycaemic response, individual preferences, affordability, cardiovascular disease, heart failure, chronic kidney disease, body-weight effects and hypoglycaemia risk.[13][14][15]
• Provide prompt, age-appropriate insulin treatment for type 1 diabetes and unstable type 2 diabetes, with intensive multiple-injection or pump regimens supporting near-physiological insulin replacement in children and adolescents.[13][16][17]
• Prevent, identify and manage cardiovascular, renal, eye, nerve and foot complications through glycaemic and blood-pressure control, lipid management, systematic screening, early specialist referral and multidisciplinary treatment.[18][19][20][21][22][23]
• Reduce avoidable acute illness, hospital admission and mortality by improving management of hypoglycaemia, intercurrent illness, diabetic ketoacidosis, hyperosmolar hyperglycaemia and pregnancy-related risks.[24][25][26][27][28]
• Support equitable, life-course care for children, adolescents, pregnant women, older people, hospitalised patients and people fasting for religious observance, with treatment adapted to clinical, psychosocial, social, cultural and economic circumstances.[9][29][30][31][32][33]

Implementation

Implement care through coordinated, patient-centred multidisciplinary services that connect primary care, diabetes specialists, hospitals, educators, dieticians, mental-health professionals and relevant referral services. Treatment planning should be agreed with patients and, where appropriate, families or carers, and should combine clinical assessment, education, self-management support, regular review and timely escalation of care.[3][11][12][34]

• Adapt recommendations using evidence from the World Health Organization, International Diabetes Federation, National Institute for Health and Care Excellence, American Diabetes Association, European Association for the Study of Diabetes and primary research where necessary; grade evidence and recommendation strength to support consistent practice.[2]
• Establish coordinated care plans led by general practitioners and diabetes teams, with access to diabetologists, nurses, dieticians, mental-health professionals, ophthalmology, nephrology, foot-care and other specialist services according to need.[3][35][20][36]
• Develop diabetes education capacity through train-the-trainer centres and training at least one health professional as a diabetes educator in every primary-care unit, while providing education at diagnosis and at continuing intervals for patients, families and caregivers.[11][12][37]
• Enable self-management through training in blood-glucose monitoring, insulin administration, carbohydrate adjustment, hypoglycaemia treatment, sick-day rules, foot care and the use of agreed treatment-adjustment algorithms.[7][24][16][38][31]
• Apply targeted screening and follow-up schedules for high-risk adults, gestational diabetes, kidney disease, retinopathy, neuropathy, cardiovascular risk and diabetic foot disease, using risk stratification to determine review frequency and referral urgency.[5][6][19][21][36][23]
• Deliver structured emergency and inpatient care through documented diabetes status, glucose monitoring, scheduled insulin where required, intravenous insulin for critical illness or metabolic instability, and discharge education on insulin use and self-monitoring.[30][39][26][28]
• Integrate psychosocial assessment into routine care, including assessment of depression, social and economic resources, quality of life, adherence barriers and family or caregiver support.[12][24][29]
• Use shared information systems, common data formats and quality indicators to collect individual and facility-level data, assess compliance with scientific standards, support clinical decisions and drive continuous improvement.[34][39]
• Support school participation through individual care plans agreed by the diabetes team and parents or guardians, access to supplies and testing, and trained school staff able to respond to hypoglycaemia.[39]
• Provide pre-fast risk assessment, treatment adjustment, nutrition advice and glucose-monitoring education for people considering Ramadan or other religious fasting, advising against prolonged fasting for those at high risk of hypoglycaemia or complications.[32][33][40]

Monitoring & Evaluation

The guidance frames monitoring as continuous measurement, analysis and improvement of diabetes care, combining patient-level clinical review with quality indicators and information systems that can assess service performance.[39]Clinical targets and review intervals are extensively specified, but national reporting schedules, surveillance governance and formal accountability arrangements are generally not defined.[1][39]

• Measure glycated haemoglobin (HbA1c) every 3–6 months until glucose control and therapy are stable, then every 6 months; use self-monitoring of plasma glucose where HbA1c testing is unavailable or not standardised.[5][7]
• Use HbA1c and blood-glucose targets to guide treatment adjustment, with goals individualised for age, pregnancy, comorbidities, life expectancy, hypoglycaemia risk and treatment burden.[7][8][14]
• Monitor high-risk people annually for progression from prediabetes to diabetes, reassess glucose tolerance 6–12 weeks after gestational diabetes, and continue subsequent diabetes or prediabetes screening.[6][3]
• Assess diabetes initially and at review for complications, prior treatment, risk-factor control, psychosocial status, adherence and self-management needs.[3][12][24]
• Use evidence levels ranging from large randomised trials or systematic reviews to uncontrolled case studies, and grade recommendation strength from A, highly recommended, to E, strongly not recommended.[2]
• Establish shared information systems and common data formats across diabetes-care facilities to support data exchange and the definition and use of clinical indicators.[34]
• Require diabetes care units to plan monitoring, measurement and analysis activities, using valid, precise, accurate, reproducible and practicable indicators derived from routine service data.[39]

Complication monitoring is detailed. Blood pressure should be reviewed every one to two months until controlled; urine albumin excretion and estimated glomerular filtration rate should be assessed at least annually for specified diabetes groups; and renal function and potassium require monitoring when relevant medicines are used.[18][19]Retinal examination intervals range from two-yearly where no retinopathy is present to annual or earlier review where disease is detected or worsening.[21]Foot assessment should occur at least annually, with follow-up every 4–12 weeks for moderate risk and every four weeks for high risk.[22][36]

Paediatric monitoring includes HbA1c measurement at least every three months, access to HbA1c testing in all diabetes centres, and comparison of HbA1c variation between centres to assess care quality.[41]During illness, children require more frequent glucose and ketone checks, at least every three to four hours including overnight and sometimes every one to two hours.[42]In hospital, case records should document capillary glucose results and hypoglycaemia episodes, while unexplained hyperglycaemia should prompt HbA1c testing.[30]

The guidance also defines acute-care monitoring, including repeated blood-glucose testing during hypoglycaemia until two normal values are obtained without further treatment, and monitoring of glucose, electrolytes, ketones, pH, bicarbonate, hydration, consciousness and clinical response in diabetic ketoacidosis.[24][27][28]It does not specify consolidated national indicator targets, public reporting requirements, audit cycles, a surveillance registry, or a named body responsible for enforcing accountability.[39]

Costing & Financing

Financial content is limited: the guidance recognises resource stewardship, cost-effectiveness, affordability and the direct and indirect economic burden of diabetes, but does not provide a consolidated budget, costed implementation plan, funding source, allocation, funding gap or economic forecast.[2][18]

• Consider the rational use of human and economic resources when adapting international recommendations to Egyptian circumstances.[2]
• Use fasting plasma glucose as the preferred screening basis where appropriate, as it is described as having a more favourable cost-effectiveness ratio than oral glucose tolerance testing.[5]
• Consider two-yearly retinal examinations after one or more normal examinations, which may be cost-effective; a three-year interval after a normal examination was associated with essentially no risk of significant retinopathy in a well-controlled type 2 diabetes population.[20][21]
• Consider medicine expense, local cost-effectiveness and patient affordability alongside efficacy, safety, tolerability, cardiovascular effects, body-weight effects and hypoglycaemia risk when selecting glucose-lowering therapy.[13][11][14]
• Recognise diabetes self-management education as an integrated intervention within national health services that should be acknowledged and paid for, although no payment mechanism or allocation is specified.[12][34]
• Account for potentially resource-intensive inputs, including diabetes educators, dietitians, specialist teams, glucose and ketone monitoring, insulin-delivery supplies, ophthalmology, foot clinics, revascularisation, wound care and hospital management of acute complications.[11][23][43][26]

Cardiovascular disease is identified as a major contributor to diabetes-related direct and indirect costs, while acute and chronic complications are associated with increased healthcare costs and personal disability.[18][37]Some high-cost interventions are qualified by affordability, including PCSK9 inhibitors and specialist-supported glucagon-like peptide-1 receptor agonist treatment.[14][18]

No monetary prices, unit costs, programme expenditure, donor commitments, insurance arrangements, financial responsibilities, resource-mobilisation measures or quantified financing gaps are specified.[15][20][44]